Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 26, 2025
Discovery & Translation
Science Spotlight: New insight into LAG3’s checkpoint function
BioCentury’s roundup of translational innovations also includes a blood-based T cell assay for T1D, a degrader using a new E3 ligase, and papers from newcos
BioCentury | Jul 26, 2024
Finance
Public Equity Report: Palvella lands on NASDAQ via Pieris merger
Plus: Verastem’s follow-on and Hangzhou Jiuyuan’s IPO plans
BioCentury | Jan 26, 2023
Product Development
Jan. 25 Quick Takes: Merck reports mixed Phase III Keytruda results
Plus: updates from Verastem, Vertex-CRISPR and Genentech
BioCentury | May 13, 2022
Regulation
May 13 Quick Takes: China proposes exclusivity for orphan, pediatric drugs
Plus FDA approves Lilly’s Mounjaro, Akebia loses partner, UCB psoriasis candidate hits FDA snag, and updates from Mitsubishi, BridgeBio and more
BioCentury | Mar 10, 2022
Product Development
March 9 Quick Takes: Pfizer and Sobi’s factor VIII therapy meets Phase III endpoints
Plus Adaptive retools, adds CFO, and updates from InxMed, Bayer, Twist-Kriya and more
BioCentury | Oct 1, 2021
Translation in Brief
Mapping protein interaction networks to uncover new cancer targets
Plus: OncoCyte, MISER, GSK and more
BioCentury | Sep 10, 2020
Finance
Sept. 9 Quick Takes: OncoImmune, Inversago raise B rounds; plus Trillium-Pfizer, Biofourmis, LinkDoc, Singleron, Hrain, InxMed and MilleporeSigma
OncoImmune raises $56M series BOncoImmune Inc. raised $56 million in a series B round co-led by HM Capital and an undisclosed investor. Also participating were fellow new investors GBA Fund and GF
BioCentury | Feb 28, 2020
Finance
Verastem raises $100M, plots path forward with targeted cancer combo
The biotech will scale back some commercial operations for Copiktra as it tests a newly acquired pipeline asset
BioCentury | Nov 14, 2019
Targets & Mechanisms
Impaired wound healing: CD47’s latest safety hurdle?
New study adds wound healing problems to list of AEs CD47 companies need to monitor
Items per page:
1 - 10 of 84